Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Trajenta Meets Primary Endpoint in Cardiovascular Trial
Trajenta Meets Primary Endpoint in Cardiovascular Trial
Trajenta Meets Primary Endpoint in Cardiovascular Trial
Submitted by
admin
on July 19, 2018 - 9:47am
Source:
CP Wire
News Tags:
Boehringer Ingelheim
Eli Lilly
Trajenta
Headline:
Trajenta Meets Primary Endpoint in Cardiovascular Trial
snippet:
Trajenta demonstrated cardiovascular safety in adults with type 2 diabetes and high vascular risk, with no need for dose adjustments regardless of kidney function
The study included 6,979 adults with type 2 diabetes and high cardiovascular risk
Do Not Allow Advertisers to Use My Personal information
